| Nicholas Capozzoli & Peter Schilder, Md, Pa | |
|
122 Defense Hwy Suite 100 Annapolis MD 21401-7069 | |
| (410) 263-9490 | |
| (410) 263-9593 |
| Full Name | Nicholas Capozzoli & Peter Schilder, Md, Pa |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 122 Defense Hwy, Annapolis, Maryland |
| Authorized Official Name and Position | Nicholas A Capozzoli (PRESIDENT) |
| Authorized Official Contact | 4102639490 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Capozzoli & Peter Schilder, Md, Pa 122 Defense Hwy Suite 100 Annapolis MD 21401-7069 Ph: (410) 263-9490 | Nicholas Capozzoli & Peter Schilder, Md, Pa 122 Defense Hwy Suite 100 Annapolis MD 21401-7069 Ph: (410) 263-9490 |
| NPI Number | 1598804957 |
|---|---|
| Provider Enumeration Date | 02/05/2007 |
| Last Update Date | 07/08/2010 |
| Medicare PECOS PAC ID | 0345347019 |
|---|---|
| Medicare Enrollment ID | O20070515000404 |
News Archive
Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.
The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598804957 | NPI | - | NPPES |
| E2380001 | Other | DC | CAREFIRST BLUE SHIELD |
| LL23NI | Other | MD | CAREFIRST BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | DOO1668O (Maryland) | Primary |
| Provider Name | Nicholas A Capozzoli |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1871632232 PECOS PAC ID: 8426951245 Enrollment ID: I20040129000658 |
News Archive
Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.
The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
› Verified 6 days ago
News Archive
Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.
The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.
› Verified 6 days ago
Tricia Burke, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1187 Saint George Dr, Annapolis, MD 21409 Phone: 808-341-4742 | |
Lumate Florida Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3151 Catrina Ln, Annapolis, MD 21403 Phone: 917-304-0679 | |
Guiding Minds Therapeutic Counseling Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2525 Riva Rd, Annapolis, MD 21401 Phone: 240-277-3422 | |
Grow On Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1702 Marissa Way, Annapolis, MD 21401 Phone: 443-203-8469 | |
Lee F. Owens, Ed.d. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 116 Defense Hwy, Suite 210, Annapolis, MD 21401 Phone: 410-224-2021 Fax: 410-224-2420 | |
Project Chesapeake Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 108 Old Solomons Island Rd, Building 2 Suite 1, Annapolis, MD 21401 Phone: 443-214-5097 Fax: 443-378-8538 | |
Rogue River Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2007 Tidewater Colony Dr Ste 1a, Annapolis, MD 21401 Phone: 410-294-9300 Fax: 410-294-9300 |